Related Experiment Videos
Cisapride for intractable constipation in children: observations from an open trial
R D Murray1, B U Li, H J McClung
1Department of Pediatrics, Ohio State University, Columbus Children's Hospital 43205.
Journal of Pediatric Gastroenterology and Nutrition
|November 1, 1990
Summary
Cisapride improved encopresis and stool consistency in children with chronic constipation. This prokinetic agent offered significant symptom relief, allowing withdrawal of other therapies in most cases.
Area of Science:
- Pediatric Gastroenterology
- Pharmacology
Background:
- Chronic constipation is a common pediatric issue.
- Many children with functional constipation are refractory to standard treatments like emollients and laxatives.
Purpose of the Study:
- To evaluate the efficacy and safety of Cisapride, an investigational prokinetic agent, in children with chronic constipation.
- To assess Cisapride's impact on encopresis, stool consistency, and need for disimpaction.
Main Methods:
- A study was conducted on twelve pediatric patients (8 boys, 4 girls) aged 2-13 years with chronic constipation.
- Patients received Cisapride (0.14-0.3 mg/kg/dose) for 26-72 weeks.
- Outcomes measured included stool frequency, consistency, encopresis, urinary complaints, and need for disimpaction.
Main Results:
- Cisapride significantly improved stool consistency in 5 of 7 patients and resolved encopresis in 8 of 10 cases.
- The need for alternative anticonstipation therapies decreased significantly (p < 0.001).
- Urinary symptoms improved in 2 of 3 affected patients; side effects were infrequent and mild.
Conclusions:
- Cisapride demonstrates significant efficacy in managing chronic constipation, particularly encopresis and stool hardness, in pediatric patients.
- It offers a valuable therapeutic option for refractory cases, potentially reducing the need for other interventions.
- The agent was generally well-tolerated with a favorable safety profile in this cohort.